Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT06979141
Recruiting Phase 3

Dexmedetomidine, Magnesium Sulphate and Lidocaine for Cough Suppression After General Anesthesia

NCT06979141 · tracked via the Priya Life Science Egypt tracker
Sponsor
Al-Azhar University
Phase
Phase 3
Started
2025-06-02
Last updated
2025-06-11

Condition(s) studied

Cough

Investigational drug(s) / intervention(s)

Dexmedetomidine →Magnesium sulfate →Lidocaine →normal saline

Dexmedetomidine: Patients will receive 0.5 μg/kg dexmedetomidine in 10ml normal saline 10 min before the end of surgery.

Magnesium sulfate: Patients will receive 30 mg/kg IV magnesium sulfate 50% 10 min before the end of surgery.

Lidocaine: Patients will receive lidocaine 1.5 mg/kg lidocaine 10 min before the end of surgery.

normal saline: Patients will receive 10 ml normal saline 10 min before the end of surgery.

Study summary

The aim of this prospective randomized controlled double-blinded study is to compare the efficacy of dexmedetomidine, MgSO4 and lidocaine for cough suppression during general anesthetic emergence as regard number and severity.

Eligibility

Sex
ALL
Min age
21 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 21-60 years. * Both genders. * Body mass index \< 30 kg/ m2 * American Society of Anesthesiology (ASA) physical status I-II. * Mallampati score class I or II. * Patients undergoing surgery under general anesthesia. Exclusion Criteria: * Known allergy to study drugs. * History of psychiatric illness. * Patients with major organ diseases. * Pre-existing neurological deficits. * Body mass index \>30 kg/m2. * Active airway infection or history of tracheal and laryngeal surgery. * Lower esophageal sphincter incompetence (and reflux). * Increased intracranial and intraocular pressure. * Use of cough-inducing medications * Pregnant, and lactating women.

Primary outcome measure(s)

  • Cough suppression as regard number and severity. — at 0 and 10,20,30,40 minutes after endotracheal extubation.
    Coughing severity will be classified using the 3 point scale described by Minogue et al.: 1 = mild, single cough, 2 = moderate (lasting for \<5 seconds) cough, and severe (lasting for \>5 seconds) cough.

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine, Al-Azhar university Assiut, Egypt. Asyut Egypt Recruiting

More Al-Azhar University trials in Egypt

Evaluation of Different Attachments on Implant-Retained Mandibular Overdenture. Recruiting
Impact of Various Acceleration Techniques on En-masse Retraction of Maxillary Anterior Teeth Starting soon
Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma: Safety and Cosmetic Outcomes Starting soon
Laboratory and Ultrasound Findings and Response to Letrozole in PCOS Patients Starting soon
Artificial Intelligence for the Diagnosis of Gingivitis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06979141 on ClinicalTrials.gov ↗ ← All trials in Egypt